![](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/06/shutterstock_2412285753.jpg)
Sobi scores EU approval for haemophilia A replacement therapy Altuvoct
The European Commission has granted marketing authorisation to Sobi’s Altuvoct (efanesoctocog alfa) for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. The Commission also upheld the European Medicines Agency (EMA) …